An overview on 5α-reductase inhibitors

  title={An overview on 5$\alpha$-reductase inhibitors},
  author={Saurabh Aggarwal and Suresh Thareja and Abhilasha Verma and Tilak Raj Bhardwaj and Manoj Kumar},
Role of 5α-reductase inhibitors in benign prostatic diseases
This review will discuss the important clinical trials of 5α-reductase inhibitors in the treatment of benign prostatic diseases and the role of dihydrotestosterone in these patients.
Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
BBR can be used as a therapeutic agent for BPH by controlling hyperplasia of prostate through suppression of ERK mechanism, confirming BBR can relieve overgrowth of prostate via ERK-dependent signaling.
Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase
The results suggest a potential pharmaceutical feature of CA in the treatment of BPH, where TP-induced proliferation and elevated AR, PSA and p-ERK were all reduced by CA treatment.
5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
Using in vitro models for urothelial cancer, 5α-RI treatment even at supra-pharmacological doses was found to have no significant impact on the prevention of both tumorigenesis and tumor progression.
Hormonal manipulation of benign prostatic hyperplasia
New 5-ARIs seem to be the promising agents that need further study, and recent data indicate that prostate shrinkage is induced by the direct inhibitory action of GHRH and of LHRH antagonists exerted through prostatic receptors.
Targeting 5α-reductase for prostate cancer prevention and treatment
The two largest trials to investigate the use of the 5α-reductase inhibitors (5ARIs) finasteride and dutasteride in patients with prostate cancer have shown that, although the incidence of cancer was reduced by 5ARI treatment, those cancers that were detected were more aggressive than in patients treated with placebo.
Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer
  • L. Schmidt, D. Tindall
  • Biology, Medicine
    The Journal of Steroid Biochemistry and Molecular Biology
  • 2011
Vanillic acid attenuates testosterone-induced benign prostatic hyperplasia in rats and inhibits proliferation of prostatic epithelial cells
In the VA treatment group, the prostate weight was reduced, and the histological changes including the epithelial thickness and lumen area were restored like in the normal control group, suggesting a new and potential pharmaceutical therapy of VA in the treatment of BPH.
Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications
The role of the differential expression of 5-AR in the normal development of the human prostate and in the pathogenesis and progression of BPH and PCa is discussed.


Inhibitors of 5α-reductase in the treatment of benign prostatic hyperplasia
By inhibiting the production of dihydrotestosterone locally within the prostate gland, 5alpha-reductase inhibitors have the effect of reducing prostate volume, improving lower urinary tract symptoms, increasing peak urinary flow, and decreasing the risk of acute urinary retention and need for surgical intervention.
Dutasteride: a novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia
Dutasteride has been shown to possess tumour regression properties invitro and its role in chemoprevention of prostate cancer will be confirmed in the ongoing Reduction by Dutasterside of Prostate Cancer Events (REDUCE) trial.
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo and reduction in its level with 5alpha-reductase inhibitors improves the symptoms associated with BPH and reduces the risk of acute urinary retention and prostate surgery.
Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
Of particular importance for BPH therapy are uroselective alpha(1)-AR antagonists for which the hypotensive related side-effect caused by alpha( 1)-AR blockade is reduced and 5alpha-Reductase inhibitors, which reduce prostate volume and symptom scores, while increasing peak urinary flow rates.
Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Dutasteride has been shown to decrease the absolute risk of urinary retention and the need for prostate-related surgery when compared to placebo taken over a 24-month period.
Selective non-steroidal inhibitors of 5α-reductase type 1
Steroid 5α-Reductase Inhibitors
To synthesize new steroidal compounds based on the progesterone skeleton with a high inhibitory activity for the enzyme 5α-reductase, which has become a pharmacological strategy for the design and synthesis of new antiandrogenic drugs.
Novel aromatase and 5α-reductase inhibitors
Effects of 5α-reductase inhibitors on intraprostatic androgens in the rat